North America Pharmaceutical Drug Delivery Market Size, Share & Trends Analysis Report By Route of Administration, By Application (Respiratory & Other Diseases, Cancer, Diabetes, and Cardiovascular Diseases), By Country and Growth Forecast, 2023 - 2030

North America Pharmaceutical Drug Delivery Market Size, Share & Trends Analysis Report By Route of Administration, By Application (Respiratory & Other Diseases, Cancer, Diabetes, and Cardiovascular Diseases), By Country and Growth Forecast, 2023 - 2030


The North America Pharmaceutical Drug Delivery Market would witness market growth of 3.4% CAGR during the forecast period (2023-2030).

Controlled-release drug delivery systems offer a sustained and prolonged release of medications over an extended period. This reduces the frequency of administration and helps maintain therapeutic drug levels in the bloodstream. Extended-release formulations are commonly used for chronic conditions, such as pain management, where around-the-clock relief is desired. The administration of chronic diseases, including diabetes, cardiovascular disease, and autoimmune disorders, depends heavily on drug delivery technology. Continuous and controlled drug delivery is essential for maintaining optimal therapeutic levels. Insulin pumps, transdermal patches, and inhalation devices are examples of drug delivery systems designed for the long-term management of chronic conditions.

The advent of biologics and gene therapies has spurred advancements in drug delivery to ensure the effective administration of these complex molecules. Nanoparticle-based carriers and specialized delivery platforms protect biologics from degradation and facilitate targeted delivery to specific cells or tissues. Drug delivery systems are adapted to meet pediatric and geriatric populations' unique needs. Pediatric formulations may involve flavored liquids or oral dissolvable films, while geriatric patients may benefit from simplified dosing regimens or controlled-release formulations. Drug delivery technologies are utilized to overcome the blood-brain barrier and enhance the delivery of medications to the central nervous system. This is crucial for the treatment of neurological disorders, such as Alzheimer’s disease and Parkinson’s disease.

According to the Centers for Disease Control and Prevention, six out of ten Americans suffer from at least one chronic condition, including diabetes, cancer, heart disease, or a stroke. The leading causes of death and disability in the US are these and other chronic disorders, dramatically raising healthcare costs. The aging population in America is more susceptible to chronic diseases. Many individuals in America are managing multiple chronic conditions simultaneously. Hence, the factors mentioned above will drive the regional market growth.

The US market dominated the North America Pharmaceutical Drug Delivery Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $513.7 Billion by 2030. The Canada market is experiencing a CAGR of 5.8% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 4.8% during (2023 - 2030).

Based on Route of Administration, the market is segmented into Injectable Drug Delivery, Oral Drug Delivery, Topical Drug Delivery, Nasal Drug Delivery, and Ocular Drug Delivery. Based on Application, the market is segmented into Respiratory & Other Diseases, Cancer, Diabetes, and Cardiovascular Diseases. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Pfizer, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Amgen, Inc.
  • Sanofi S.A.
  • Cipla Limited
  • Merck & Co., Inc.
North America Pharmaceutical Drug Delivery Market Report Segmentation

By Route of Administration
  • Injectable Drug Delivery
  • Oral Drug Delivery
  • Topical Drug Delivery
  • Nasal Drug Delivery
  • Ocular Drug Delivery
By Application
  • Respiratory & Other Diseases
  • Cancer
  • Diabetes
  • Cardiovascular Diseases
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pharmaceutical Drug Delivery Market, by Route of Administration
1.4.2 North America Pharmaceutical Drug Delivery Market, by Application
1.4.3 North America Pharmaceutical Drug Delivery Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Geographical Expansions
4.2.5 Trials & Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2021-2024)
4.3.2 Key Strategic Move: (Mergers & Acquisition: 2021, Aug – 2023, Oct) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. North America Pharmaceutical Drug Delivery Market, by Route of Administration
5.1 North America Injectable Drug Delivery Market, by Country
5.2 North America Oral Drug Delivery Market, by Country
5.3 North America Topical Drug Delivery Market, by Country
5.4 North America Nasal Drug Delivery Market, by Country
5.5 North America Ocular Drug Delivery Market, by Country
Chapter 6. North America Pharmaceutical Drug Delivery Market, by Application
6.1 North America Respiratory & Other Diseases Market, by Country
6.2 North America Cancer Market, by Country
6.3 North America Diabetes Market, by Country
6.4 North America Cardiovascular Diseases Market, by Country
Chapter 7. North America Pharmaceutical Drug Delivery Market, by Country
7.1 US Pharmaceutical Drug Delivery Market
7.1.1 US Pharmaceutical Drug Delivery Market, by Route of Administration
7.1.2 US Pharmaceutical Drug Delivery Market, by Application
7.2 Canada Pharmaceutical Drug Delivery Market
7.2.1 Canada Pharmaceutical Drug Delivery Market, by Route of Administration
7.2.2 Canada Pharmaceutical Drug Delivery Market, by Application
7.3 Mexico Pharmaceutical Drug Delivery Market
7.3.1 Mexico Pharmaceutical Drug Delivery Market, by Route of Administration
7.3.2 Mexico Pharmaceutical Drug Delivery Market, by Application
7.4 Rest of North America Pharmaceutical Drug Delivery Market
7.4.1 Rest of North America Pharmaceutical Drug Delivery Market, by Route of Administration
7.4.2 Rest of North America Pharmaceutical Drug Delivery Market, by Application
Chapter 8. Company Profiles
8.1 GlaxoSmithKline PLC (GSK)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 F. Hoffmann-La Roche Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Trials & Approvals:
8.2.6 SWOT Analysis
8.3 Bayer AG
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Acquisition and Mergers:
8.3.5.3 Geographical Expansions:
8.3.6 SWOT Analysis
8.4 Pfizer, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional & Segmental Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Johnson & Johnson
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental & Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Cipla Limited
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Merck & Co., Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.6 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings